American journal of cancer research最新文献

{"title":"Effects of warming needle moxibustion on postoperative rehabilitation, pain degree, immune function, and upper limb lymphedema in patients with breast cancer undergoing radical mastectomy.","authors":"Kanghua Zheng, Xiaoping Hong, Changyin Jiang, Yong Chen","doi":"10.62347/YXHG6188","DOIUrl":"https://doi.org/10.62347/YXHG6188","url":null,"abstract":"<p><p>This study aims to evaluate the effects of warm acupuncture combined with conventional functional rehabilitation training (FRT) on the recovery of breast cancer (BC) patients following radical mastectomy, focusing on immune function, pain management, and quality of life (QoL). This retrospective study involved 118 BC patients who underwent radical surgery at the Second People's Hospital Affiliated to Fujian University of Chinese Medicine between January 2022 and May 2024. The included patient were assigned into an experimental group (EG, n=62, warm acupuncture in conjunction with conventional FRT) and a control group (CG; n=56; conventional FRT only). Postoperative outcomes, including surgery duration, intraoperative blood loss (IOBL), drainage volume (DV), length of hospital stay, upper limb mobility, immune function indicators, and pain scores, were compared between the two groups. Multivariate logistic regression was employed to identify factors affecting treatment outcomes. The EG demonstrated significantly lower visual analog scale (VAS) scores at post-operative 2, 4, and 8 weeks compared to the CG (all <i>P</i> < 0.05). The incidence of upper limb lymphedema in the EG was 9.26%, notably lower than the 24.07% observed in the CG (<i>P</i> < 0.05). Immune function indicators, including CD3⁺, CD4⁺, CD8⁺, and the CD4⁺/CD8⁺ ratio, were significantly higher in the EG postoperatively (<i>P</i> < 0.05). Furthermore, the EG reported significantly improved scores in role physical, general health, vitality, social functioning, role emotional, mental health, and physiological functioning, alongside significantly lower scores in bodily pain compared to the CG (all <i>P</i> < 0.05). Multivariate logistic regression analysis revealed CD3⁺ and CD4⁺/CD8⁺ ratio as independent factors affecting patient treatment efficacy (both <i>P</i> < 0.05). In conclusion, the combination of warm acupuncture and conventional FRT significantly enhances immune function, pain management, and overall QoL in BC patients after surgery, with CD3⁺ and CD4⁺/CD8⁺ ratios being crucial factors influencing recovery.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"991-1001"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of febrile neutropenia in small cell lung cancer patients receiving concurrent chemoradiotherapy with etoposide and cisplatin: a focus on nutritional status, inflammation, and performance status.","authors":"Weiping Zhang, Yongchen Sun, Yiming Li","doi":"10.62347/JRMG1142","DOIUrl":"https://doi.org/10.62347/JRMG1142","url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) is a rapidly proliferating malignancy with a poor prognosis, commonly treated with concurrent chemoradiotherapy based on the etoposide and cisplatin (EP) regimen; however, this treatment is often complicated by febrile neutropenia (FN), a potentially life-threatening condition that can compromise treatment efficacy and patient safety. The aim of this study was to identify risk factors for FN in SCLC patients undergoing EP-based concurrent chemoradiotherapy to enhance treatment outcomes and improve patient management. In this retrospective case-control study, data from 216 SCLC patients who underwent concurrent chemoradiotherapy with the EP regimen between September 2014 and January 2020 were analyzed. Patients were categorized into FN (n = 106) and non-FN (n = 110) groups. Various clinical factors, including body mass index (BMI), Eastern Cooperative Oncology Group Performance Status (ECOG PS), and pre-treatment laboratory values such as albumin, IL-6, and C-reactive protein (CRP), were examined. Statistical analyses, including univariate and multivariate logistic regression, were performed to identify independent risk factors for FN. Lower BMI (<i>P</i> = 0.016) and poorer ECOG Performance Status (<i>P</i> = 0.001) were associated with an increased risk of FN. Additionally, pre-albumin levels (<i>P</i> = 0.010), inflammatory markers CRP (<i>P</i> = 0.032), and IL-6 (<i>P</i> = 0.001) also showed significant associations, suggesting that nutritional status and systemic inflammation play important roles in the development of FN. Importantly, multivariate logistic regression analysis confirmed pre-albumin levels (<i>P</i> = 0.003), IL-6 level (<i>P</i> = 0.001), MASCC score (<i>P</i> < 0.001), and ECOG PS (<i>P</i> = 0.019) as independent factors for FN risk. These findings highlight the importance of nutritional status, systemic inflammation, and overall health condition in predicting FN occurrence, underscoring the need for integrated risk assessment and management strategies to mitigate FN risk in SCLC patients undergoing EP-based concurrent chemoradiotherapy.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1020-1035"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct genomic features and mutational signatures of nucleotide excision repair and mismatch repair in thymoma.","authors":"Po-Liang Cheng, Wei-Jan Wang, Cheng-Yen Chuang, Chih-Hung Lin, Chih-Yang Huang, Tzu-Hung Hsiao, Chung-Ping Hsu","doi":"10.62347/ZWSB8391","DOIUrl":"https://doi.org/10.62347/ZWSB8391","url":null,"abstract":"<p><p>Thymoma is a rare malignancy with an unclear etiology of occurrence and development. We observed a higher incidence of thymoma in the Taiwanese population compared to other Western populations, suggesting the existence of different genomic features. Since most genomic studies are based on Western populations, we aimed to characterize the genomic profile of the Taiwanese population and compare it to the TCGA cohort in this study. We analyzed the genome of 47 thymoma patients using the Tumor Mutational Burden Panel to discover the genetic profile of the Taiwanese population. We also characterized the mutational signatures of these samples. Additionally, we leveraged RNA seq to estimate the gene expression profile and explored the featured pathways of thymoma in the Taiwanese population through gene set enrichment analysis.We identified several frequently mutated genes related to transcription, such as FAT1, KMT2D, and ZFHX3, as well as consensus mutational signatures associated with nucleotide excision repair (NER) and mismatch repair (MMR) deficiency. Our study also revealed increased activity of NER and MMR functions in our study cohort. Upon comparison with the TCGA cohort, we found dramatic differences in the most frequently mutated genes and mutational profiles between the Taiwanese and TCGA cohorts. Furthermore, we identified mismatch repair deficiency as a Taiwanese population-specific mutational signature with higher activity. These results highlight the distinct genomic background and molecular mechanisms of thymoma in the Taiwanese population, which may contribute to the development of new diagnostic and therapeutic strategies in the future.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1189-1200"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of behavioral activation on depressive symptoms in colorectal cancer patients within a medical environment: the mediating role of physical activity.","authors":"Anlong Li, Han Ge, Runze Huang, Dajie Liu, Shaochun Liu, Yingxue Jia, Jiaying Chai, Xinyi Zheng, Lijun Liu, Chen Gan, Jian Xu, Ling Cheng, Mingjun Zhang, Huaidong Cheng","doi":"10.62347/PNHN9442","DOIUrl":"https://doi.org/10.62347/PNHN9442","url":null,"abstract":"<p><p>Colorectal cancer (CRC) treatment often affects patients' quality of life, leading to depressive symptoms. Behavioral activation (BA) therapy, which increases engagement by enhancing positive reinforcement and reducing avoidance, has shown potential in managing these symptoms. Physical activity (PA) is also known to alleviate depression, though its role as a mediator in BA's effectiveness remains unclear. This clinical trial was retrospectively registered in ClinicalTrials.gov on April 5, 2024 (Effects of Behavioral Activation on Negative Emotions, Cancer-related Symptoms and Clinical Indicators in Cancer Patients, NCT06348940). This study explores PA's mediating effect within BA interventions. A total of 109 CRC patients with depressive symptoms were randomly assigned to a BA group (n=52) or a Usual Care (UC) group (n=57). Assessments occurred at baseline (T0), after the fourth session (T1), and post-intervention (T2). The BA group showed significant improvement compared to the UC group. Repeated measures ANOVA confirmed BA's effectiveness in reducing depressive symptoms, improving quality of life, alleviating psychological distress, increasing activation, and raising PA levels. PA changes accounted for 36.91% of the intervention's total effect on depression reduction. BA effectively reduces depression and enhances life quality in CRC patients. Changes in PA intensity are significantly associated with depression reduction, suggesting PA's mediating role in BA's impact. Incorporating PA into BA may enhance therapeutic outcomes for CRC patients with depression.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1264-1279"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of BromAc^® with Mitomycin C during hyperthermic intraperitoneal chemotherapy (HIPEC): a preclinical study.","authors":"Ahmed H Mekkawy, Mohammad Breakeit, Md Khalilur Rahman, Krishna Pillai, Anant Solanki, Fany Octavia, Samina Badar, Javed Akhter, Sarah J Valle, David L Morris","doi":"10.62347/HQJH9945","DOIUrl":"https://doi.org/10.62347/HQJH9945","url":null,"abstract":"<p><p>Peritoneal cancer patients are often treated with hyperthermic intraperitoneal chemotherapy (HIPEC). BromAc^®, a mixture of bromelain and acetylcysteine, has demonstrated anticancer properties with chemotherapeutic agents. Although bromelain and acetylcysteine have anti-inflammatory, anti-coagulant and wound healing properties, their effect with Mitomycin C is unknown in HIPEC. Hence, we investigated their safety using a rat model. Sixteen Wistar rats were divided into 4 groups (N=4). Controls received saline, whilst the others received BromAc^®, Mitomycin C (MMC) or BromAc^®+MMC. Three doses were given at 30-minute intervals. Animal weights were monitored for 7 days before euthanasia. Peritoneal fluid and blood samples were collected for pharmacokinetic analysis. Colon anastomosis healing was evaluated with burst pressure and collagen density assessment. Internal organ histology and coagulation factor X were performed in plasma with an enzyme-linked immune assay. All rats were healthy, with similar weight fluctuation patterns, although the MMC-treated rats, with or without BromAc^®, showed higher weight loss during the first 4 days. Whilst the burst pressure was similar in all groups, the BromAc^® group showed a slightly higher value. Collagen densities were similar in all groups. The results showed that the histology of vital organs of the treated and controls were similar. BromAc^® concentration in peritoneal fluids increased over 90 min with a higher increase when given with MMC. BromAc^® or the combination did not affect coagulation Factor X. In conclusion, general well-being, wound healing, organ histology, pharmacokinetics and coagulation factor evaluations indicated that BromAc^® with or without MMC was safe during HIPEC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1213-1223"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FTO-mediated m6A modification of QPCT promotes tumorigenesis in lung adenocarcinoma by inducing macrophage chemotaxis and M2 polarization.","authors":"Benkun Liu, Yubo Yan, Junnan Guo, Jianlong Bu, Jian Zhang, Lantao Chen, Fucheng Zhou, Jinfeng Ning, Shidong Xu","doi":"10.62347/RGDP9493","DOIUrl":"https://doi.org/10.62347/RGDP9493","url":null,"abstract":"<p><p>Lung adenocarcinoma (LUAD), the most common histologic subtype of lung cancer, is characterized by malignant and high infiltrating. Glutaminyl-peptide cyclotransferase (QPCT) promotes cancer progression by modifying the N-terminus of chemokine C-C motif ligand 2 (CCL2) to a pyroglutamate residue and stabilizing the protein. The role of QPCT in LUAD is still unknown. QPCT mRNA and protein expression were up-regulated in clinical LUAD specimens. By generating stable HCC44 cells with QPCT overexpression and stable A549 cells with QPCT knockdown, we found that QPCT knockdown notably inhibited LUAD cell proliferation. Additionally, QPCT deletion reduced the CCL2 contents in LUAD cell supernatants and inhibited phorbol 12-myristate 13-acetate-induced THP-1 macrophage chemotaxis toward tumor cells or tumor cell conditioned medium. The CD68⁺/CD206⁺ cell ratio was reduced by QPCT deletion <i>in vitro</i>. Nude mice inoculated with parental A549 or cells with stable QPCT knockdown were used to explore QPCT functions. The results were consistent with <i>in vitro</i> experiments. QPCT is predicted to be modified by N6-methyladenosine (m6A), and we performed methylated RNA immunoprecipitation PCR to confirm this result in A549 cells. The m6A demethylase fat mass and obesity-associated protein (FTO) mRNA expression positively correlated with QPCT mRNA in LUAD samples. FTO bound to QPCT mRNA and FTO knockdown affected QPCT mRNA stability. FTO deletion in HCC44 cells abrogated the macrophage recruitment and macrophage M2 polarization induced by QPCT overexpression. In conclusion, QPCT promotes tumorigenesis in LUAD by increasing macrophage recruitment and M2 macrophage proportion. This may be due to FTO-mediated demethylation increasing the QPCT mRNA stability.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1036-1050"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma.","authors":"You-Na Sung, Mi-Ju Kim, Sun-Young Jun, Yeon Wook Kim, Jihyun Park, Sung-Wuk Jang, Tae Jun Song, Ki Byung Song, Seung-Mo Hong","doi":"10.62347/OVUJ4436","DOIUrl":"https://doi.org/10.62347/OVUJ4436","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a poor prognosis. While venous invasion is believed to contribute to liver metastasis and an unfavorable prognosis, the precise mechanisms involved remain unclear. Here, we conducted gene expression profiling on eight PDAC tissue samples exhibiting portal venous invasion (VI group) compared to PDAC samples without portal venous invasion (CA group) and normal portal vein tissues (NV group). A subset of genes, including tissue inhibitor of metalloproteinase 1 (<i>TIMP1</i>), C-X-C motif chemokine receptor 4 (<i>CXCR4</i>), olfactomedin-like 2B (<i>OLFML2B</i>), and cytochrome P450 family 1 subfamily B member 1 (<i>CYP1B1</i>), was found to be specifically expressed in the PDAC group with venous invasion. Immunohistochemical staining of 15 cases revealed significantly higher levels of <i>TIMP1</i> (P=.026) and <i>CXCR4</i> (P<.001) in the VI set compared to the CA set. In addition, the PDAC group with strong TIMP1 expression had a higher frequency of lymphovascular invasion (P<.001) and lower 5-year survival rates than the PDAC group with no/weak <i>TIMP1</i> expression (P=.027). Specific <i>TIMP1</i> expression in the venous invasion foci was highlighted on 3D reconstruction imaging. Invasion assays and/or Western blot analyses were performed on pancreatic cancer cells (Panc1), cancer-associated fibroblasts (CAFs), and human endothelial cells (EA.hy926). TIMP1 inhibition suppressed cancer cell invasion in the presence of CAFs. TIMP1 expression increased with PI3Kp110, phospho-AKT, and phospho-ERK1/2 in Panc1 cells co-cultured with CAFs and EA.hy926 endothelial cells. Our data demonstrate that TIMP1 in pancreatic cancer cells promotes venous invasion of PDACs by activating the PI3K/AKT and ERK1/2 pathways in collaboration with CAFs and endothelial cells. Therefore, TIMP1 may serve as a biomarker for venous invasion in PDACs.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1248-1263"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct triangular comparison of tissue and serum growth differentiation factor 15 with host factors in colorectal cancer.","authors":"Shinji Yamashita, Yoshinaga Okugawa, Koki Higashi, Yuki Sato, Takashi Ichikawa, Ryo Uratani, Takahito Kitajima, Tadanobu Shimura, Hiroki Imaoka, Mikio Kawamura, Yuhki Koike, Hiromi Yasuda, Shigeyuki Yoshiyama, Yoshiki Okita, Masaki Ohi, Yuji Toiyama","doi":"10.62347/WTCF3616","DOIUrl":"https://doi.org/10.62347/WTCF3616","url":null,"abstract":"<p><p>Growth differentiation factor 15 (GDF-15) is a potential biomarker for colorectal cancer (CRC) and is associated with sarcopenia and cachexia. However, its clinical significance in CRC remains unclear. We investigated the clinical significance of GDF-15 in CRC patients by a unique triangular comparison of tissue and preoperative serum GDF-15 levels with host factors. We evaluated 428 tissue and 214 serum samples from 214 CRC patients. We measured tissue and serum levels of GDF-15 and assessed their association with oncological outcomes and host factors. While cancer tissue GDF-15 levels showed no significant associations with clinicopathological factors or survival, preoperative serum GDF-15 levels were significantly correlated with indicators of disease progression, such as advanced T stage and advanced pathological stage. High preoperative serum GDF-15 level was associated with poor disease-free survival and overall survival and was an independent prognostic factor for disease-free survival and overall survival. Significant correlations were observed between preoperative serum GDF-15 levels and host factors, including body mass index, psoas muscle mass index, intramuscular adipose tissue content, and C-reactive protein. In conclusion, preoperative serum GDF-15 reflects host factors such as body composition and inflammation and is a useful marker for the oncological management of CRC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1174-1188"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of systemic inflammatory response markers NLR, PLR, and MLR in advanced high-risk endometrial cancer following radiotherapy.","authors":"Liang Ma, Yumeng Zhang, Yuheng Shao, Li Luo, Jinglan Zhou, Junbo Wu, Yanqing Wang, Chaoqian Zhao","doi":"10.62347/YYNW9957","DOIUrl":"https://doi.org/10.62347/YYNW9957","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the relationship between systemic inflammatory response markers and the short-term prognosis of patients with endometrial cancer after comprehensive treatment.</p><p><strong>Methods: </strong>This retrospective study analyzed the baseline data from 156 endometrial cancer patients who received postoperative radiotherapy at the gynecology department of ChangZhi People Hospital Affiliated to ChangZhi Medical College. Optimal cutoff values for preoperative hematological indicators were determined using receiver operating characteristic (ROC) curves. The Kaplan-Meier method was used for univariate analysis to describe survival time and the 5-year overall survival rate of patients, as well as to plot the survival curve for endometrial cancer. Multivariate regression analysis was employed to identify independent risk factors for patient survival prognosis and to establish a multivariate prediction model.</p><p><strong>Results: </strong>By the end of the follow-up period, 42 patients (26.9%) were alive, and 114 patients (73.1%) had died. The shortest survival period was 21 months, the longest was 73 months, and the median survival time was 51 months. The 5-year survival rate was 39.3%. The prognostic nomogram model for endometrial cancer included 7 risk factors: age, pathological stage, interval time to postoperative chemotherapy, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). The Hosmer-Lemeshow test result for this model showed that the area under the ROC curve was 0.995 (95% CI: 0.989-1.000), with an optimal cutoff value of 0.485, a sensitivity of 0.951, and a specificity of 0.71616. The internal validation results of the model showed a C-index of 0.995, indicating a good fit and high predictive value of the model.</p><p><strong>Conclusion: </strong>Pre-treatment peripheral blood levels of PLR, NLR, and MLR were higher in deceased patients who received postoperative radiotherapy for advanced endometrial cancer compared to survivors. A multivariate prediction model based on preoperative and intraoperative baseline data can effectively predict patient prognosis.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"966-975"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.","authors":"Yingchuan Zhu, Yue Song, Wenhao Jiang, Jingfei Zhang, Lan Yin, Xinyu Lin, Yilu Lu, Dachang Tao, Yongxin Ma","doi":"10.62347/SQUF6988","DOIUrl":"https://doi.org/10.62347/SQUF6988","url":null,"abstract":"<p><strong>Objective: </strong>To systematically characterize tumor-associated macrophage (TAM) subsets in lung adenocarcinoma (LUAD) and establish a TAM-based prognostic risk signature for LUAD patients.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data were integrated to identify TAM subsets linked to LUAD prognosis. Prognostic genes were screened using univariate Cox regression, refined via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and used to construct a 10-gene risk signature. The signature's performance was validated in independent cohorts through receiver operating characteristic curves, Kaplan-Meier survival analysis, and a nomogram. Its predictive ability for immune checkpoint inhibitor (ICI) therapy response was assessed in the IMvigor210 and GSE78220 datasets.</p><p><strong>Results: </strong>Six distinct TAM subpopulations were identified, with two subsets significantly correlated with poor prognosis. The 10-gene risk signature, derived from TAM-related genes, demonstrated strong prognostic performance in both training and validation cohorts. High-risk patients exhibited markedly worse overall survival compared to low-risk patients. Additionally, the signature effectively stratified patients based on their response to anti-PD-L1 therapy, with high-risk patients exhibiting reduced clinical benefit. A nomogram combining the risk signature with clinicopathological parameters further enhanced survival prediction accuracy, supporting its clinical applicability.</p><p><strong>Conclusion: </strong>This study established a novel TAM-based prognostic risk signature with robust predictive power for both survival outcomes and immunotherapy response in LUAD. These findings enhance our understanding of TAMs' clinical significance and provide a foundation for personalized immunotherapy strategies in LUAD.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"876-893"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}